FDA Halts Clinical Test of Zafgen Diabetes Drug, Stock Price Tumbles | Enterpreneurship

The FDA has ordered Zafgen to suspend a mid-stage study testing its experimental diabetes drug, an apparent precautionary move.

A clinical hold halts patient enrollment and also stops already enrolled patients from receiving the study drug due to a potential safety risk. No safety problems have been reported for the drug, ZGN-1061, so far. But Zafgen (NASDAQ: ZFGN) said Monday that the FDA’s letter cited the “possibility of cardiovascular safety risk” based on the company’s earlier obesity drug, which acts in a similar way as ZGN-1061. Two years ago, the deaths of two patients in a late-stage study of the… Read more »

Reprints | Share:

UNDERWRITERS AND PARTNERS